Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $25.00 at BTIG Research

Health Catalyst (NASDAQ:HCATGet Rating) had its price objective trimmed by BTIG Research from $35.00 to $25.00 in a report issued on Wednesday, The Fly reports.

HCAT has been the subject of a number of other research reports. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $35.00 to $17.00 in a research report on Wednesday, May 11th. Guggenheim initiated coverage on shares of Health Catalyst in a research report on Wednesday, April 13th. They issued a buy rating and a $39.00 target price for the company. The Goldman Sachs Group cut their price target on shares of Health Catalyst from $42.00 to $37.00 and set a buy rating on the stock in a report on Thursday, May 26th. Royal Bank of Canada cut their price target on shares of Health Catalyst from $35.00 to $19.00 in a report on Wednesday, May 11th. Finally, Citigroup cut their price target on shares of Health Catalyst from $45.00 to $25.00 in a report on Wednesday, May 11th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Health Catalyst presently has a consensus rating of Buy and an average target price of $33.17.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $15.91 on Wednesday. The company has a market cap of $862.08 million, a PE ratio of -5.13 and a beta of 1.07. Health Catalyst has a 52 week low of $11.25 and a 52 week high of $59.50. The firm has a 50 day simple moving average of $14.92 and a 200 day simple moving average of $21.34.

Health Catalyst (NASDAQ:HCATGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03. Health Catalyst had a negative net margin of 57.95% and a negative return on equity of 19.88%. The company had revenue of $68.09 million during the quarter, compared to the consensus estimate of $66.01 million. During the same quarter in the prior year, the firm earned ($0.37) EPS. The company’s revenue was up 21.9% compared to the same quarter last year. On average, equities analysts predict that Health Catalyst will post -1.83 earnings per share for the current year.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Linda Llewelyn sold 1,860 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $15.87, for a total value of $29,518.20. Following the sale, the insider now directly owns 60,173 shares in the company, valued at approximately $954,945.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Health Catalyst news, General Counsel Daniel H. Orenstein sold 2,838 shares of the firm’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $14.85, for a total value of $42,144.30. Following the sale, the general counsel now directly owns 103,671 shares in the company, valued at approximately $1,539,514.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 1,860 shares of the firm’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $15.87, for a total transaction of $29,518.20. Following the completion of the sale, the insider now owns 60,173 shares in the company, valued at $954,945.51. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,255 shares of company stock worth $93,877. 1.50% of the stock is owned by insiders.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fairfield Bush & CO. acquired a new stake in shares of Health Catalyst during the 1st quarter valued at about $25,000. UMB Bank N A MO acquired a new stake in shares of Health Catalyst during the 4th quarter valued at about $30,000. Manchester Capital Management LLC boosted its position in shares of Health Catalyst by 667.5% during the 1st quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock valued at $30,000 after acquiring an additional 1,008 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Health Catalyst during the 1st quarter valued at about $33,000. Finally, Sageworth Trust Co of South Dakota acquired a new stake in shares of Health Catalyst during the 4th quarter valued at about $61,000. 97.53% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Read More

The Fly logo

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.